The Carle Health Heart and Vascular team is focused on bringing the benefits of research and education to our patients. Through our leadership in research and clinical trials, patients have access to innovative cardiovascular devices and therapies that aren’t yet broadly available. And as a center for postgraduate education, our physicians are leading the way in the latest diagnostic techniques, treatments, therapies and other innovations. At Carle Health, our patients are at the heart of everything we do.
Our team is uniquely structured with all cardiovascular disciplines working together as one team: Cardiovascular Medicine, Cardiac Surgery, Vascular Surgery and Interventional Radiology. This close collaboration means that we can deliver a higher standard of care and a more seamless experience for patients. It also means that we’re able to offer a comprehensive range of cardiovascular programs and services close to home – the complexity of which is often only available at large academic programs in major cities.
Have a patient referral? Refer a patient now.
We work closely with the Stephen’s Family Clinical Research Institute to offer patients leading-edge therapies through clinical trials. Our physician investigators (cardiologists, cardiac surgeons, vascular surgeons and radiologists) are involved in multiple national and investigator-initiated studies that span the field of pharmacotherapy and interventional devices. Also, we are actively involved in translational research activities in collaboration with the Beckman Institute for Advanced Science and Technology.
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
The TECTONIC CAD IVL IDE Study is a prospective, single-arm, open-label, multi-center study to evaluate the safety and effectiveness of the Abbott Coronary IVL System to treat severely calcified, stenotic de novo coronary arteries prior to stenting in 335 subjects at up to 55 sites in the US. The clinical outcomes from the study will be compared to pre-specified performance goals (PG) established using medical/scientific literature. This clinical investigation will be conducted under an investigational device exemption (IDE) and is intended to support market approval of the Abbott Coronary IVL System in the United States.
The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
With doctors practicing in 80 specialties at locations throughout the region, it’s easy to find the right healthcare team at Carle. Our mission is to serve people through high quality care, medical research and education.
“With Jac and other afib patients, we aim to minimize or prevent recurrence for as long as possible and restore quality of life.”
DONATE NOW READ FULL ARTICLERecognized among the nation’s top hospitals, Carle provides excellent healthcare while continuously improving to meet the needs of our patients.